RadioMedix
RadioMedix is developing AlphaMedix (212Pb-DOTAMTATE) with Orano Med, the first targeted alpha therapy to receive FDA Breakthrough designation.
AlphaMedix met all primary efficacy endpoints in phase 2 (60% ORR in PRRT-naive GEP-NET patients, ESMO 2025); licensed to Sanofi with Orano Med in 2024; next trial planned for late 2026. RadioMedix marked 20 years at SNMMI 2026.
Pages like this
not linked directly; found by shared links- TrialALPHAMEDIX-02
Shares 212Pb-DOTAMTATE, Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- TrialCOMPETE
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.
- CompanyRayzeBio (BMS)
Shares Peptide receptor radionuclide therapy (PRRT), Targeted alpha therapy, Neuroendocrine tumours.
- CompanyITM Isotope Technologies Munich
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Targeted alpha therapy, Neuroendocrine tumours.
- PairingBeta PRRT → alpha PRRT
Shares 212Pb-DOTAMTATE, Targeted alpha therapy, Neuroendocrine tumours.
- PairingSSTR PET → PRRT
Shares Peptide receptor radionuclide therapy (PRRT), Somatostatin receptor 2, Neuroendocrine tumours.